Babraham, United Kingdom

Timothy David Jones

USPTO Granted Patents = 35 

 

Average Co-Inventor Count = 4.6

ph-index = 8

Forward Citations = 359(Granted Patents)


Location History:

  • Cambs, GB (2016 - 2017)
  • Cambridgeshire, GB (2011 - 2022)
  • Babraham, GB (2015 - 2024)

Company Filing History:

goldMedal5 out of 986 
 
Emory University
 patents
silverMedal5 out of 1,206 
 
Dana-farber-cancer Institute Inc.
 patents
bronzeMedal5 out of 45 
 
Celldex Therapeutics Limited
 patents
43 out of 121 
 
Intrexon Corporation
 patents
53 out of 4 
 
Famewave Ltd.
 patents
62 out of 1,269 
 
University of North Carolina at Chapel Hill
 patents
72 out of 366 
 
Research Corporation Technologies, Inc.
 patents
82 out of 250 
 
Biogen Ma Inc.
 patents
91 out of 1 
 
Interxon Corporation
 patent
101 out of 3 
 
Antitope Limited
 patents
111 out of 2 
 
Kolltan Pharmaceuticals, Inc.
 patents
121 out of 65 
 
Boyce Thompson Institute for Plant Research
 patents
131 out of 1 
 
Nkt Therapeutics Inc.
 patent
141 out of 1 
 
Therapix Biosciences Ltd.
 patent
151 out of 5 
 
C2n Diagnostics LLC
 patents
161 out of 768 
 
Ramot at Tel-aviv University Ltd.
 patents
171 out of 3 
 
Amyl Therapeutics Srl
 patents
181 out of 10,170 
 
Schlumberger Technology Corporation
 patents
191 out of 8 
 
Proclara Biosciences, Inc.
 patents
201 out of 446 
 
Oxford University Innovation Limited
 patents
211 out of 8 
 
Vasgene Therapeutics, Inc
 patents
where one patent can have more than one assignee

Years Active: 2011-2024

Loading Chart...
Loading Chart...
35 patents (USPTO):Explore Patents

Title: **Timothy David Jones: Innovator in Antibody Therapeutics**

Introduction

Timothy David Jones is a distinguished inventor based in Babraham, GB, known for his groundbreaking work in the field of antibody therapeutics. With a remarkable portfolio of 35 patents, his contributions have significantly advanced the understanding and treatment of various diseases, particularly those related to cancer and KIT-associated disorders.

Latest Patents

His latest innovations include two significant patents:

1. **Anti-KIT Antibodies and Uses Thereof**

This patent presents antibodies that specifically bind to the human KIT antigen, particularly targeting the fourth and fifth extracellular Ig-like domains. These antibodies play a crucial role in inhibiting KIT activity, which is vital for treating or managing disorders associated with this receptor. The patent also outlines methods for diagnosing KIT-associated diseases using these antibodies, along with associated pharmaceutical compositions.

2. **Anti-MET Antibodies and Methods of Use Thereof**

This patent involves antibodies designed to bind to MET, a receptor tyrosine kinase that is important in cancer pathways. The innovation includes methods to modulate the expression of MET and ways to manage, treat, or prevent cancer through the use of monoclonal antibodies targeting the Sema/PSI domain of human MET. The patent also details the development of kits comprising these antibodies for therapeutic use.

Career Highlights

Timothy's career includes significant roles at esteemed institutions, such as Emory University and the Dana-Farber Cancer Institute. His research has focused on therapeutic applications of monoclonal antibodies, establishing him as a leader in the biotechnology field.

Collaborations

Throughout his career, Timothy has collaborated with esteemed professionals, including Francis Joseph Carr and Francis J Carr. These partnerships have facilitated advancements in research and the development of innovative therapeutics.

Conclusion

Timothy David Jones exemplifies the spirit of innovation in biotechnology. His extensive patent portfolio demonstrates his commitment to improving patient outcomes through targeted therapies, particularly in the realm of cancer treatment. As he continues to work at the intersection of science and medicine, his contributions are likely to pave the way for future breakthroughs in antibody therapeutics.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…